Authors
Latest:
Dr. Lee on Choosing Among Antiandrogens in Nonmetastatic CRPCRichard (Rick) JaeBong Lee, MD, PhD, discusses choosing among the antidrogens available in the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Latest:
Unraveling Neuroendocrine Tumors: Clinician Reflects on 60 Years of DiscoveryRichard R.P. Warner, MD, discusses the key learnings and insights of 60 years of studying, diagnosing, and treating patients with neuroendocrine tumors and carcinoid syndrome.
Latest:
Primary Results from the Phase 3 Leap-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-Line Therapy for Advanced Hepatocellular CarcinomaDr Finn reviews the results from the Leap-002 study which evaluates the use of lenvatinib with pembrolizumab in the front-line setting for patients with advanced hepatocellular carcinoma.
Latest:
Final Thoughts on the Future of Liver CancerA panel of experts lead by Richard S. Finn, MD, provide their final thoughts on the future of advanced unresectable liver cancer.
Latest:
Dr. Pelman on Determining Treatments for Newly Diagnosed Prostate CancerRichard S. Pelman, MD, president of the American Association of Clinical Urologists and an urologist at the University of Washington Department of Urology, discusses techniques for selecting patients for radical prostatectomy or watchful waiting and active surveillance.
Latest:
Dr. Richard Stock on Brachytherapy for Prostate CancerRichard Stock, MD, a professor of radiation oncology at the Icahn School of Medicine at Mount Sinai Hospital, talks about brachytherapy and its benefits for patients with prostate cancer.
Latest:
Concluding Thoughts on the DLBCL Treatment LandscapeDLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.
Latest:
Dr. Penson on Olaparib Monotherapy Vs Chemo in Ovarian CancerRichard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Massachusetts General Hospital, compares olaparib (Lynparza) monotherapy with chemotherapy for patients with relapsed germline BRCA-mutated (gBRCAm) platinum-sensitive ovarian cancer.
Latest:
Dr. Penson on PARP Inhibitors as Switch Maintenance Therapy in Recurrent Ovarian CancerRichard T. Penson, MD, MRCP, discusses selecting between PARP inhibitors for switch maintenance therapy in recurrent ovarian cancer.
Latest:
Dr. Richard Silver Discusses the High Cost of Drugs in CMLRichard T. Silver, MD, from the New York Presbyterian-Weill Cornell Medical Center, comments on the cost of drugs to treat chronic myeloid leukemia.
Latest:
Dr. Joseph on Molecular Signatures in mRCCRichard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses molecular signatures in metastatic renal cell carcinoma (mRCC).
Latest:
Novel Approach Reduces Treatment Toxicities in Patients With HPV-Related Oropharyngeal CancerThe incidence of mouth and throat cancer is on the rise due to transmission of the human papilloma virus, but physicians at Memorial Sloan Kettering Cancer Center have managed to significantly reduce the intensity of treatment and improve quality of life for these patients.
Latest:
Challenges in Treating Chemotherapy-Induced AnemiaPracticing clinicians and healthcare administrators face many challenges in treating cancer patients, including management of chemotherapy-induced anemia.
Latest:
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic AstrocytomaRimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.
Latest:
Early Findings Support Novel Regimen for Unresectable HCCAtezolizumab (Tecentriq) plus bevacizumab (Avastin) resulted in clinically meaningful and durable objective responses as first-line therapy for patients with previously untreated, unresectable disease.
Latest:
Dr Nanda on Treatment De-Escalation in HER2+ Breast Cancer and TNBCRita Nanda, MD, discusses efforts to de-escalate adjuvant therapy for patients with select breast cancers who responded to neoadjuvant therapy.
Latest:
Dr Nanda on Neoadjuvant Treatment in HER2+ Breast CancerRita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.
Latest:
Dr Salani on Research With MEK Inhibition in KRAS-Mutant Serous Ovarian CancerRitu Salani, MD, MBA, discusses pathways implicated in low-grade serous ovarian cancer that may be viable for targeted therapy development.
Latest:
Memory-Like Natural Killer Cells for Patients With Advanced AML and MDSAcute myeloid leukemia and myelodysplastic syndromes are the two most common hematologic malignancies of the myeloid lineage origin and both are more common in older patients.
Latest:
Dr. Friedman on the Future of Selinexor in Multiple MyelomaRobb S. Friedman, MD, discusses the future of selinexor in multiple myeloma.
Latest:
Dr. Burger on Bevacizumab Toxicity in Ovarian CancerRobert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the toxicity profile of bevacizumab when used to treat patients with ovarian cancer.
Latest:
Dr. Figlin on Novel Combinations in Kidney Cancer TreatmentRobert A. Figlin, MD, discusses novel combinations in the treatment of patients with kidney cancer.
